HPV Vaccine Has the Potential Against Six Viral Strains

HPV Vaccine Has the Potential Against Six Viral StrainsKnowing to target two vital cancer-causing strains of the virus, the human papilloma virus vaccine Cervarix, can serve with many more similar benefits, finds a new study.

Researchers from the study found that Cervarix along with treating two cancer-causing strains also helps in partially protecting the body against four more viral strains, which counts the list of total affected strains of cancer in the body to six, a cause of approximately 85% cervical cancers.

“The study provides data to substantiate the benefits of HPV vaccination [programs], and health-care professionals should be encouraged to aim for a high vaccine uptake”, Mr. Matti Lehtinen at the University of Tampere in Finland and colleagues reported today in the Lancet Oncology.

To conclude some firm results, Lehtinen included approx 20,000 healthy women aged between 15-25 years in his study, which ran for four years. About 50% of the total number of women were prescribed the HPV vaccine in three doses and the remaining 50% were given a control hepatitis A vaccine.

It was noted by the researchers during the study that the HPV vaccine showed 93% better effects in women against grade 3 cervical intraepithelial neoplasia and eventually 100% effects against adenocarcinoma in situ, both of which can easily develop into cervical cancer.

On the other hand, women who were kept unvaccinated were 46% protected against CIN, and 77% against AIS, confirmed the study.

Lehtinen and his colleagues further wrote in their suggestions highlighting the benefits of HPV vaccine that the vaccination is potential enough to reduce the risks of cervical cancer in teenagers as well but only if teens get themselves vaccinated against the illness before getting involved in sexual activities.